GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
While it was developed and validated for brain tumor classification, the workflow could be extended to other cancers where intraoperative histology is valuable.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
